High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinsons Disease With Dementia
Conditions
Parkinsons Disease With Dementia
Trial Timeline
Jul 9, 2018 → Sep 30, 2020
NCT ID
NCT03774459About High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule
High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule is a phase 2 stage product being developed by Anavex Life Sciences for Parkinsons Disease With Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT03774459. Target conditions include Parkinsons Disease With Dementia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03774459 | Phase 2 | Completed |
| NCT03790709 | Phase 2/3 | Completed |
Competing Products
5 competing products in Parkinsons Disease With Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirabegron + Placebo | Astellas Pharma | Approved | 85 |
| Rivastigmine Patch 9.5 cm2 | Novartis | Approved | 85 |
| Prasinezumab + Placebo | Roche | Phase 2 | 52 |
| ALN-SNCA + Placebo | Regeneron Pharmaceuticals | Phase 1 | 32 |
| bemdaneprocel | Bayer | Phase 3 | 74 |